The answer is yes. PROVE 1 data released last month indicate that TVR (VRTX's drug) is effective in bringing down the viral counts to a undetectable (UND) level very quickly (within a few weeks of treatment) for most treatment-naive patients.
Projecting from the time development of the percentage of UND patients in the course of PROVE 1 trial, I am optimistic about the chance of cure for this group of HCV patients if they are treated with TVR + IFN + RBV for 10 wks and continued with IFN + RBV for another 40 wks or so. I would put the chance of cure for such a regimen to be somewhere around 80%. However, if the regimen is changed to a shorter duration such as 12 wk +12 wk, the chance of cure would drop below 70% for the first-timer genotype 1 patients. These are very qualitative predictions of my own.
The fact that close to 50% of patients of this group can be cured with IFN + RBV alone and a probably better outcome with addition of TVR indicates to me that HCV virus does not infect and disable the immune system which destroys the virus. This is a different topic we were discussing earlier.